• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Can Antidepressants Prolong Survival in Cancer Patients?

Can Antidepressants Prolong Survival in Cancer Patients?

May 21, 2021
Paul Barkopoulos, MD.
From The Carlat Hospital Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Paul Barkopoulos, MD. Dr. Barkopoulos has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review Of: Shoval G et al, Depress Anxiety 2019;36(10):921–929

Many cancer patients experience depression, especially those with poor prognoses. Compared with euthymic patients, depressed cancer patients are less adherent to their cytotoxic medications, and this poor adherence can worsen their long-term survival. Yet surprisingly, some studies have reported a higher mortality rate among cancer patients taking antidepressants—but might confounding factors account for this finding (eg, patients with worse prognoses are more likely to be depressed and therefore to be placed on antidepressants)?

This large (n = 42,075) retrospective cohort study controlled for several confounding factors to get a better understanding of the relationship between antidepressant use and mortality. Using an Israeli national health services database, the authors extracted data on patients who were diagnosed with cancer and purchased an antidepressant prescription within the 4-year study period (2008–2012). Patients were further divided into subgroups based on antidepressant adherence, ranging from non-adherent to highly adherent. Adherence was defined as the number of months with actual filled prescriptions divided by the number of months when an antidepressant was prescribed.

An initial analysis indicated an increase in mortality with antidepressant adherence, but also revealed that older and sicker patients tended to be the most adherent, leading to an over-representation of mortality in the adherent group.

A subsequent analysis, adjusting for such factors, showed the opposite: Patients who were adherent to their antidepressant lived significantly longer than patients who were minimally adherent (< 20% adherent) or non-adherent. The mortality rate among patients with the highest antidepressant adherence (> 80% adherent) was 20% lower, over the study period, compared to the non-adherent or minimally adherent group. Subgroup analyses showed this adherence benefit remained regardless of cancer type, including lung, prostate, breast, and colon cancer.

CHPR’s Take
This large retrospective study found that antidepressant adherence was associated with improved survival in people with cancer. Whether this is due to greater adherence to cancer treatment or some other reason remains unclear. The study should further our resolve to treat depression and anxiety in cancer patients, and to encourage patients to not miss doses of their antidepressants.
Hospital Psychiatry
KEYWORDS adherence cancer citalopram depression escitalopram fluoxetine mortality paroxetine prozac serotonin-specific-reuptake-inhibitors-ssris sertraline ssris
Paul Barkopoulos, MD.

QT Intervals in Psychiatric Practice

More from this author
www.thecarlatreport.com
Issue Date: May 21, 2021
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Capacity Assessments, CHPR, April/May/June 2021
Finally, Effective Treatments for Tardive Dyskinesia
Decisional Capacity
Capacity Assessment in Pregnant Patients
Suvorexant May Prevent Delirium in Hospitalized Patients
SSRIs and Intracerebral Hemorrhage Risk
Can Antidepressants Prolong Survival in Cancer Patients?
Hyperprolactinemia: Effective Treatment With Aripiprazole
Note From the Editor-in-Chief
DOWNLOAD NOW
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    Treating Alcohol Use Disorder: A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto104192710.jpg
    Hospital Psychiatry

    Management of Depression and Neurocognitive Impairment in Patients With HIV

    Strategies for the evaluation and management of HIV-associated mood and cognitive changes and potential drug interactions between psychiatric and antiretroviral medications. 

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.